Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Inventory (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Inventory for 10 consecutive years, with $70.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Inventory rose 52.39% year-over-year to $70.0 million, compared with a TTM value of $70.0 million through Sep 2025, up 52.39%, and an annual FY2024 reading of $53.2 million, up 26.24% over the prior year.
  • Inventory was $70.0 million for Q3 2025 at Heron Therapeutics, down from $73.0 million in the prior quarter.
  • Across five years, Inventory topped out at $73.0 million in Q2 2025 and bottomed at $100000.0 in Q1 2024.
  • Average Inventory over 5 years is $48.6 million, with a median of $48.4 million recorded in 2021.
  • The sharpest move saw Inventory crashed 99.81% in 2024, then soared 56832.0% in 2025.
  • Year by year, Inventory stood at $48.4 million in 2021, then increased by 12.8% to $54.6 million in 2022, then decreased by 22.84% to $42.1 million in 2023, then increased by 26.24% to $53.2 million in 2024, then skyrocketed by 31.72% to $70.0 million in 2025.
  • Business Quant data shows Inventory for HRTX at $70.0 million in Q3 2025, $73.0 million in Q2 2025, and $56.9 million in Q1 2025.